Aerosol formulations of granisetron useful for pulmonary delivery are provided. The formulations are useful in the reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) using the inhalation formulations.

Provided herein are compositions and methods for treating and preventing lung disease. In particular, provided herein are surfactant protein-A (SP-A) peptide analogies (e.g., SP-A peptidomimetics) and uses thereof in the treatment and prevention of lung disease (e.g., asthma or COPD).

The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.

The present invention relates to a novel propellant-gas-containing medicament composition based on tiotropium 1, processes for the preparation thereof and the use of such medicament compositions in the treatment of respiratory complaints.

The present disclosure relates to the administration of a composition comprising an interferon, azithromycin and chloroquine for the treatment of respiratory conditions.

A pharmaceutical composition for aerosol administration and method of preventing or treating a pulmonary disease or condition in a subject with a SphK1 inhibitor are provided.

The present invention provides compositions and methods for the treatment of diseases and disorders. In some embodiments the compositions and methods involve administration of a microparticle, or composition thereof that includes an antifibrotic.

Aerosol formulations of granisetron useful for pulmonary delivery are provided. The formulations are useful in the reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) using the inhalation formulations.

The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.

A therapeutic emulsion is provided comprising a perfluorocarbon emulsion and a therapeutic agent, such as tobramycin. Methods of making and using the emulsion are provided. A method of treating a lung infection is provided.